We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Asia,Middle East
Monthly Production Capacity: 50,000 vials
Packaging Information: A pack of JITIDE contains a vial of white to off-white lyophilised powder containing 1,6 mg of active substance thymalfasin and an ampoule of 1 mL of solvent (Water for Injection).
Delivery Lead Time: 2 months
Sample Provided: no
Payment Terms: T/T
Thymalfasin for injection (JITIDE®), for subcutaneous or for intravenous use
Note: the content below do not include all the information needed to use Thymalfasin for injection safely and effectively. Please read the package insert carefully and follow the doctors’ instructions before use the product.
THERAPEUTIC INDICATION
JITIDE is used in adults as influenza vaccination adjuvant for immunocompromised subjects.
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Administer, subcutaneously or intramuscularly, one vial twice a week for four weeks starting at time 0 (first vaccination).
The treatment will be repeated with the same dosage plan from the eighth (second vaccination) to the twelfth week.
Method of administration
The lyophilised powder has to be reconstituted with 1 ml of the solvent (Water for Injections); the solution must be administered immediately after reconstitution.
Paediatric population
Data about the use of thymalfasin in children and adolescents do not exist or they are limited; therefore the use of JITIDE is not recommended in children and adolescents.
DOSAGE FORMS AND STRENGTHS
For injection: 1.6 mg of Thymalfasin as a lyophilized powder in a single-dose vial for reconstitution